The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients

被引：0
|
作者：
Elisabetta Munzone
Alessandra Fabi
Giuseppe Buono
Roberta Caputo
Emilia Montagna
Mara Negri
Francesco Nuzzo
Antonella Palazzo
Ida Paris
Luca Conti
Anna Baggi
Jean Marie Franzini
Michelino De Laurentiis
机构：
[1] Istituto Europeo di Oncologia,Precision Medicine Unit in Senology
[2] IRCCS,Medical Oncology Unit Fondazione
[3] Fondazione Policlinico Universitario Agostino Gemelli,Ginaecological Oncology Unit Fondazione
[4] National Cancer Institute “Fondazione Pascale”,Life Sciences Division
[5] Policlinico Universitario Agostino Gemelli,undefined
[6] Policlinico Universitario Agostino Gemelli,undefined
[7] Business Integration Partners,undefined
来源：
Drugs & Therapy Perspectives | 2023年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：432 / 446
页数：14
相关论文
共 50 条
  • [1] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+Breast Cancer Patients
    Munzone, Elisabetta
    Fabi, Alessandra
    Buono, Giuseppe
    Caputo, Roberta
    Montagna, Emilia
    Negri, Mara
    Nuzzo, Francesco
    Palazzo, Antonella
    Paris, Ida
    Conti, Luca
    Baggi, Anna
    Franzini, Jean Marie
    De Laurentiis, Michelino
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (12) : 432 - 446
  • [2] Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)
    Swain, S. M.
    Tan, A.
    Gianni, L.
    Kummel, S.
    Dang, C.
    Schneeweiss, A.
    O'Shaughnessy, J.
    Liu, H.
    Aguila, C.
    Heeson, S.
    Macharia, H.
    Restuccia, E.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S419 - S420
  • [3] The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
    Shao, Z.
    Huang, T.
    Fan, Z.
    Wang, Y.
    Yan, X.
    Yang, H.
    Wang, S.
    Pang, D.
    Li, H.
    Wang, H.
    Geng, C.
    Huang, L.
    Siddiqui, A.
    Wang, B.
    Xie, B.
    Sun, G.
    Restuccia, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S1431 - S1431
  • [4] A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
    Ziegengeist, Julia L.
    Tan, Antoinette R.
    CLINICAL BREAST CANCER, 2025, 25 (02) : e124 - e132
  • [5] Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
    Gregori, Joaquin Gavila
    Miranda, Elena Lopez
    Escriva-de-Romani, Santiago
    Rodriguez, Begona Jimenez
    Novoa, Silvia Antolin
    Morales, Luis Fernandez
    Calvo, Elena Galve
    Cortijo, Lucia Gonzalez
    Martorell, Antonia Perello
    Ruiz, Julian Lagunar
    Santiago, Santiago Gonzalez
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
    DuMond, Barbara
    Patel, Vidhi
    Gross, Anne
    Fung, Anita
    Weber, Susan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1214 - 1221
  • [7] Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
    Dang, Chau T.
    Tolaney, Sara M.
    Riaz, Fauzia
    Tan, Antoinette R.
    Tkaczuk, Katherine H. R.
    Yu, Anthony Francis
    Liu, Jennifer
    Fung, Anita M.
    Yang, Anna
    Day, Bann-Mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis
    Sripada, Kaushik
    Manjrekar, Siddhi
    Klein-Panneton, Kristoph
    Coombes, Megan
    Ferrario, Cristiano
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.
    Manevy, Federico
    Filkauskas, Gabriele
    Levy, Pierre
    Fredriksson, Judy
    Sussell, Jesse
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S.
    Cruz, J.
    Fallowfield, L.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Machackova, Z.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S306 - S307
12345